Tech Company M&A Transactions
LigoCyte Pharmaceuticals Acquisition
On 10/8/2012, LigoCyte Pharmaceuticals was bought by Takeda Pharmaceuticals. The parties disclosed the acquisition price to be $60 million.
Transaction Overview
Company Name
Acquired By
Announced On
10/8/2012
Transaction Type
M&A
Amount
$60,000,000
M&A Terms
Takeda will acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2155 Analysis Drive
Bozeman, MT 59718
USA
Bozeman, MT 59718
USA
Phone
Website
Email Address
Overview
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Donald Beeman
Chief Medical Officer
Paul Mendelman
Chief Scientific Officer
Robert Bargatze
Controller
Larry Mikkola
President
Robert Goodwin
VP - R & D
Charles Richardson
Browse more venture capital transactions:
Prev: 10/8/2012: Tolera Therapeutics venture capital transaction
Next: 10/8/2012: Xeround venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs